Søren Berg Padkær

Title: Innovations of Søren Berg Padkær

Introduction

Søren Berg Padkær is a notable inventor based in Værløse, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of agents that enhance natural killer (NK) cell activity. With a total of seven patents to his name, Padkær's work has the potential to impact cancer treatment and immunotherapy.

Latest Patents

One of his latest patents focuses on KIR-binding agents and methods of use thereof. This invention relates to agents and methods capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signaling without diminishing the binding of KIR to HLA-C. The patent describes how the transduction of negative signaling via KIR, upon binding to its HLA class I ligand, can involve a conformational reorientation of the KIR molecules. This reorientation allows interactions to form between adjacent KIRs, leading to accelerated clustering. The methods and agents, including monoclonal antibodies, aim to reduce KIR-mediated inhibition of NK cell cytotoxicity while preserving HLA-binding.

Career Highlights

Throughout his career, Søren Berg Padkær has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Novo Nordisk A/S and Innate Pharma S.A.S. His work in these organizations has contributed to advancements in therapeutic solutions and innovative research.

Collaborations

Padkær has collaborated with esteemed colleagues, including Stefan Zahn and Peter Andreas Nicolai Reumert Wagtmann. These collaborations have fostered a productive environment for innovation and research in the field of immunotherapy.

Conclusion

Søren Berg Padkær's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in cancer treatment and immunotherapy.